Meet the team
Prosemble is led by a team of experts with deep experience in science, finance, and technology:
Dr. Julien Bergeron
CEO/ CSO
Dr. Julien Bergeron is an internationally recognised expert in protein biochemistry and biophysics, having received advanced training in the USA and Canada. As a Senior Lecturer at King’s College London, he leads a research team focused on bacterial virulence and antibiotic resistance.
Dr. Bergeron has successfully secured over £4M in research funding and has collaborated with Isomorphic Labs/Google DeepMind on AlphaFold3.
His expertise and experience in managing large research teams, combined with access to cutting-edge research facilities, position him ideally to lead the technical development of Prosemble’s nanoparticle drug delivery platform.
Inna Zhuranskaya CDir
CFO/ CIO
Ms. Inna Zhuranskaya brings over 20 years of in PE/VC experience, having held CEO/CIO roles at Allrise Capital and Yoo Group, as well as senior positions at Deutsche Bank, Bank of America, and GIC, Singapore’s sovereign wealth fund. She is a Chartered Director at the IOD, a Chartered Member of the Institute for Securities & Investments, and the University of Cambridge and the LSE’s graduate.
She has raised over £2B and led several groundbreaking transactions, including JVs with major institutional investors, such as European and Middle Eastern sovereign wealth and pension funds. Ms. Zhuranskaya has served on the boards of Alkor Bio Group and Astra Biotech GmbH, where she oversaw a JV with the University of Newcastle focused on mesenchymal stem cells’ treathment for ischemic stroke. Her deep expertise in capital raising, structuring, and leading cross-functional teams will be instrumental in securing funding and driving the business strategy for the commercialisation of Prosemble’s technology.
Marek Oleksiewicz
CTO
Mr. Marek Oleksiewicz brings extensive expertise in data science, AI, and IT, having held leadership positions at AstraZeneca, Goldman Sachs, and Deutsche Bank, where he was the Head of Quantitative Software Infrastructure and Model Risk Management. Earlier in his career, Mr. Oleksiewicz worked with Ricardo UK in R&D, programming controls and software for hybrid vehicles for the Beijing Olympics.
He holds an MSc in Electrical Engineering from Wroclaw University of Technology and further qualifications in International Securities, Investment and Banking (Quantitative Finance) from the University of Reading (ICMA Centre), as well as an MBA from Instituto de Empresa Business School, Madrid
His experience in building complex computational infrastructures and AI systems will be invaluable in optimising Prosemble’s nanoparticle technology and ensuring efficient scaling and automation of drug delivery systems.
Dr. Ludovico Pipito
AI/ML Lead. Head of Computational Chemistry
Dr. Ludovico Pipito is a computational chemist and ML engineer developing cutting-edge solutions for drug discovery. At Prosemble he bridges biochemistry and AI to reduce chemotherapy toxicity, while maintaining his academic role as Research Fellow at Coventry University. He pioneered the multiple-walker supervised molecular dynamics (mwSuMD), an unbias method to accelerate 100x the sampling of rare biochemical events, and developed scalable QM-refined HTVS pipelines for drug discovery and FEP evaluation. He also applies computational chemistry and ML to unveil the biological mechanism of depalmitoylating enzymes.
He actively collaborates with AstraZeneca on antigen-antibody epitope modelling (EpiFinder) and LLM-based molecule generation. He is specialised in drug discovery for cancer, while authoring numerous publications on SARS-CoV-2 therapeutics, HIV inhibitors, and innovative computational method development, building scalable pipelines that combine QM, FEP, and neural networks to industry standards.
Serge Platonow
Non-Executive Chairman
Mr. Serge Platonow is an accomplished executive with extensive experience in PE and investment management. He serves as Non-Executive Chairman at Prosemble. Mr. Platonow is also a Principal at the Hayrish Group, a investment firm specialising in real estate and PE. Prior to this, he held senior leadership positions at Chelsfield, a global investment and development firm, where he served as Managing Director for Europe, overseeing major capital projects.
Mr. Platonow has also worked at Colony Capital (now DigitalBridge), a leading investment firm with over £50B in AUM where he was CIO of its real estate and infrastructure arm, Colyzeo Investment Management. He has served on the boards of prestigious organisations, including Paris Saint-Germain Football Club and Lucia SA. Mr. Platonow holds an MBA from INSEAD, an MSc from the MIT. He is the son of the late Nicholas Platonow, a prominent toxicologist and advisor to the Canadian government.
Dr. Alexandra Parker
Non-Executive Director
Dr. Alexandra Parker is an accomplished structural biologist and biochemist with a PhD in Molecular Biology and Biotechnology from the University of Sheffield, where her research focused on chromosome segregation in Vibrio Cholerae, employing a multidisciplinary approach including cryo-electron microscopy and X-ray crystallography, with findings published in the Nature Communications.
Dr. Parker further developed her expertise in structural biology as a Postdoctoral Research Associate at King’s College London, broadening her focus to membrane proteins and investigating complexes involved in membrane maintenance and auto-translocation in Gram-negative bacteria. Now a Senior Scientist at Domainex, Dr. Parker brings extensive experience across academia and industry, particularly in protein expression, purification, and structural determination, playing a key role in advancing scientific innovation in drug discovery.
Sadie Hallett
Senior Scientist
Ms Sadie Hallett is a Senior Scientist with a strong academic and research background in molecular biology and cancer cell signalling. She is currently undertaking a PhD at King’s College London, where her research focuses on the role of RNA-binding proteins LARP4A and LARP4B in PKC epsilon-mediated signalling in cancer. Alongside her doctoral studies, she has worked as a Laboratory Demonstrator and contributed to a range of research projects, including investigations into SARS-CoV-2 antibody responses and CRISPR-mediated chromatin organisation.
Ms Hallett holds MBio in Biochemistry from the University of Warwick and MRes in Biomedical and Translational Science, reflecting her ongoing dedication to translational biomedical research.
Tadas Vilkas
IT Infrastructure Lead
Mr Tadas Vilkas is currently on secondment to Prosemble, bringing over a decade of experience in IT service management, operations, and project delivery. He serves as a Project Manager at SKAYLINK.LT leading complex infrastructure and integration projects with a strong focus on reliability and business continuity.
Mr Vilkas has previously held senior IT roles at Lantmännen and Vaasan Oy, where he managed service delivery across international teams and oversaw critical incident and problem management processes. He holds MSc Information Technology from the Vilnius University Šiauliai Academy with a specialisation in signal technologies and IT systems.
John Finnemore
Legal Council
Mr John Finnemore is a Partner in the CMS Corporate Team (CMS Cameron McKenna Nabarro Olswang) and serves as the Legal Council for Prosemble. He is a specialist in VC, PE and M&A, with a particular focus on advising clients in the technology sector through all funding rounds to eventual exit.
Mr Finnemore trained with a US law firm and has worked for international law firms throughout his career. He has substantial experience in PE/VC and is ranked in both the Chambers and Legal 500 guides for his expertise in this space.
Through Our Science We Are Transforming Cancer Treatment for Chemotherapy Patients
